Biomarkers to inform the management of polycystic ovary syndrome: A review of systematic reviews
Authors' conclusion
We identified 22 core biomarkers assessing the multisystemic impact of PCOS and inform its clinical management. Future research is required to establish validated healthcare pathways.
Study context
- Population
- Systematic reviews evaluating biomarkers in women with polycystic ovarian syndrome (PCOS) vs healthy controls; MEDLINE, EMBASE, CENTRAL and HTA searched until August 202375 systematic reviews
- Participants
- 191,792 participants
- Comparison
- Women with PCOS vs healthy controls
- Outcome
- Biomarkers abnormal in PCOS vs healthy controls
Methodological detailsAMSTAR2 quality assessment
- AMSTAR2 quality assessment
Main finding
As reported in the abstract
Biomarkers evaluated
88
Abnormal biomarkers in women with PCOS vs healthy controls
63
Core biomarkers to evaluate multisystemic impact and inform management and surveillance: DHEA, PRL, SHBG, total and free testosterone, AMH, systolic and diastolic BP, CRP, fibrinogen, OGTT, HOMA-IR, fasting insulin, total cholesterol, TG, lipoprotein(a), HDL, LDL, non-HDL-cholesterol, ferritin, iron, 25(OH)D
22
Further findings
- Moderate-quality reviews
- 50/75, 67%
- Reviews reporting high heterogeneity
- 66/75, 88%
Original publication
Biomarkers to inform the management of polycystic ovary syndrome: A review of systematic reviews. Clin Endocrinol (Oxf). Published 18 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →